Press Releases
Preliminary Results for the Year Ended 31 December 2014
Click here to download the full 2014 preliminary results statement – Strong clinical progress; Cat-SPIRE phase III study fully recruited – – Robust financial position; fully-funded to bring Cat-SPIRE to market – – Commercialisation preparations...
View detailsCircassia Appoints Lota S Zoth as Non-Executive Director
Click here to download full press release Oxford, UK – 9 February 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces the appointment of Lota...
View detailsNotice of Preliminary Results
Oxford, UK – 27 January 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, will announce its preliminary results for the year ended 31 December 2014 on...
View detailsCircassia Completes Recruitment for Cat Allergy Treatment Pivotal Phase III Study
Click here to download full press release – Study on track to report in H1 2016 – – 1,409 subjects randomised; 19% above target – Oxford, UK – 8 January 2015: Circassia Pharmaceuticals plc (“Circassia”...
View detailsCircassia Announces Top-Line Results from Ragweed Allergy Treatment Phase IIb Chamber Study
Click to download full press release Oxford, UK – 8 December 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces results from a phase IIb...
View detailsCircassia Interim Management Statement
Click here to download November 2014 Interim Management Statement – Strong operational progress; clinical programmes on track – – Encouraging results from third season follow-up study in grass allergy – Oxford, UK – 11 November...
View detailsInterim Results for the Six Months Ended 30 June 2014
Click here to download the full 2014 interim results statement — Successfully raised over £200 million in landmark IPO — — Fully-funded to bring to market the first of a new generation of allergy immunotherapies...
View detailsCircassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study
Click here to download full press release Oxford, UK – 13 June 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, today announces positive top-line results from a two-year...
View detailsNotice of Interim Results
Oxford, UK – 3 June 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, will be announcing its interim results for the six months ended 30 June 2014 on...
View detailsInterim management statement
May 2014 Interim Management Statement Oxford, UK – 19 May 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, today publishes its interim management statement for the period from...
View details